Ibio Incorporated (NYSEAMERICAN:IBIO) Shorted Shares Increased By 4.19%

February 13, 2018 - By Maria Brooks

 Ibio Incorporated (NYSEAMERICAN:IBIO) Shorted Shares Increased By 4.19%

Investors sentiment increased to 1.25 in 2017 Q3. Its up 0.25, from 1 in 2017Q2. It increased, as 2 investors sold iBio, Inc. shares while 2 reduced holdings. 1 funds opened positions while 4 raised stakes. 2.98 million shares or 5.47% more from 2.83 million shares in 2017Q2 were reported.
Hightower Advsr Ltd Com accumulated 135,020 shares. Northern invested 0% in iBio, Inc. (NYSEAMERICAN:IBIO). State Street invested in 12,000 shares or 0% of the stock. Virtu Llc accumulated 115,513 shares. Two Sigma Limited Liability Co reported 105,434 shares. Asset Strategies holds 0% or 10,000 shares. Pennsylvania-based Vanguard Grp Inc has invested 0% in iBio, Inc. (NYSEAMERICAN:IBIO). Royal Fincl Bank Of Canada has invested 0% in iBio, Inc. (NYSEAMERICAN:IBIO). Moreover, Signaturefd Lc has 0.01% invested in iBio, Inc. (NYSEAMERICAN:IBIO) for 152,910 shares. Blackrock reported 173,508 shares stake. Susquehanna Intll Gp Ltd Liability Partnership reported 95,974 shares. Moreover, Geode Capital Management Ltd Limited Liability Company has 0% invested in iBio, Inc. (NYSEAMERICAN:IBIO) for 342,667 shares. Morgan Stanley invested in 14,500 shares or 0% of the stock. Fifth Third Bancorp owns 2,000 shares for 0% of their portfolio. Bancshares Of Ny Mellon Corp invested 0% in iBio, Inc. (NYSEAMERICAN:IBIO).

The stock of Ibio Incorporated (NYSEAMERICAN:IBIO) registered an increase of 4.19% in short interest. IBIO’s total short interest was 323,300 shares in February as published by FINRA. Its up 4.19% from 310,300 shares, reported previously. With 658,400 shares average volume, it will take short sellers 1 days to cover their IBIO’s short positions. The short interest to Ibio Incorporated’s float is 0.41%.

The stock increased 5.05% or $0.0097 during the last trading session, reaching $0.2017. About 531,739 shares traded. iBio, Inc. (NYSEAMERICAN:IBIO) has declined 45.59% since February 13, 2017 and is downtrending. It has underperformed by 62.29% the S&P500.

iBio, Inc., a biotechnology company, focuses on developing and commercializing pharmaceutical product applications using its platform in the United States and internationally. The company has market cap of $23.28 million. The Company’s lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It currently has negative earnings. It is also developing vaccine candidates for third parties.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.